# BPC-157 TB-500 FAQ: The Wolverine Blend, Answered from the Record > BPC-157 TB-500 questions answered from the research and regulatory record — what the blend is, mechanism, synergy, tendon and wound evidence, dosing context, FDA 503A status, WADA, and the safety signals. Direct answers, cited. Definitional, mechanistic, efficacy, dosing, safety, and regulatory questions about the Wolverine blend — each answered directly and cited to the literature or the FDA record. ## What the blend is BPC-157 TB-500 is the two-peptide Wolverine blend, and this ledger answers the most common questions about it from the published record. The definitional ones come first. ### What is the Wolverine peptide blend? A research-community name for a two-peptide pairing of BPC-157 and TB-500, marketed and discussed as a tissue-repair stack. It is not a single chemical entity or an approved product, and most TB-500 efficacy data come from full-length Thymosin Beta-4 rather than the marketed fragment [4] [5]. ### What is BPC-157 and TB-500? BPC-157 is a synthetic 15-amino-acid pentadecapeptide, the cytoprotective and angiogenic component; TB-500 is a synthetic `Ac-LKKTETQ` heptapeptide from the actin-binding region of Thymosin Beta-4, the cytoskeletal and cell-migration component [3]. The Wolverine blend pairs the two, and neither is an FDA-approved drug. ### What is the BPC-157 and TB-500 blend used for in research? In animal models the constituents have been studied for tendon, ligament, muscle, and wound repair [1] [4]. All efficacy data are preclinical and single-compound, not from the blend in humans, and no controlled combination study exists [7]. ### What is the difference between BPC-157 and TB-500? BPC-157 is a 15-mer derived from a gastric-juice protein, acting via VEGFR2-Akt-eNOS [2]; TB-500 is a 7-mer fragment of Thymosin Beta-4 acting via G-actin sequestration [3]. They differ in structure, size, and mechanism. ## Why they are combined, and how they work ### Why are BPC-157 and TB-500 combined (the Wolverine stack)? The rationale is complementary mechanisms — BPC-157 supplies a local angiogenic and cytoprotective signal while TB-500 supplies an actin-sequestration and cell-migration signal — but this synergy is a theoretical extrapolation, not a finding from a controlled combination study [7]. ### How does BPC-157 work compared to TB-500? BPC-157 acts as a local angiogenic and cytoprotective signal, up-regulating VEGFR2 with downstream Akt-eNOS [2], whereas TB-500 acts intracellularly by sequestering G-actin [3]. The pathways are largely non-overlapping. ### How does TB-500 work (actin / Thymosin Beta-4)? TB-500's `LKKTETQ` motif binds monomeric G-actin 1:1 and sequesters it — structurally confirmed for Thymosin Beta-4 by `2 A` crystallography [3] — regulating the cytoskeletal dynamics that drive cell migration. ### Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)? In animal and in-vitro models, BPC-157 is pro-angiogenic via VEGFR2 up-regulation and Akt-eNOS signaling [2]; thymosin beta-4 promotes angiogenesis by endothelial migration [4]. Both are preclinical mechanisms. ## Evidence and efficacy ### Is there any study showing BPC-157 and TB-500 work better together (synergy)? No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together; the 2025 systematic review of BPC-157 makes no mention of TB-500 or combination use [7]. ### Are there human clinical trials on the BPC-157 + TB-500 combination? There are no controlled clinical trials of the combination for any indication [7]. Human data exist only for the individual constituents and are themselves thin — BPC-157 has three small pilot studies [9], and human "TB-500" data are for full-length Thymosin Beta-4 [5]. ### Does the BPC-157 TB-500 blend help tendon and ligament injuries? BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical and microscopic measures in animal studies [1]. These are preclinical, single-compound findings, not blend efficacy in humans. ### Does BPC-157 and TB-500 help muscle tears and recovery? A 2025 systematic review found BPC-157 "shows promise" for musculoskeletal recovery, but only from the lowest tiers of evidence (level IV-V) and with no clinical safety data [7]; no human blend data exist. ### Does the BPC-157 TB-500 blend help wound healing? Thymosin beta-4 accelerated re-epithelialization and collagen deposition in animal wound models and reduced myofibroblast number, meaning less scarring [4]. These are single-compound preclinical findings, not blend data in humans. ## Dosing context ### What is the half-life of BPC-157 and TB-500? BPC-157's elimination half-life was reported as under 30 minutes in animal pharmacokinetics [1]. No validated human half-life exists for either constituent at research doses, and none for the blend [5]. ### How do you reconstitute a BPC-157 / TB-500 blend (10mg)? Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated; product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [5]. This describes research handling, not a human preparation instruction. ### How often should you inject BPC-157 and TB-500? There is no validated dosing schedule for the blend; community "loading then maintenance" protocols have no controlled-trial basis [8]. Research doses are reported per body weight in animal models only [1] [4]. ### How do you cycle BPC-157 and TB-500? No validated cycling protocol exists; fixed-ratio vials (for example `10 mg` + `10 mg`) and loading/maintenance schedules circulate in the community without any controlled human-trial basis [8], and the one dose-response study available shows the highest dose can give no benefit [4]. ## Safety ### What are the side effects of BPC-157 and TB-500? There is no controlled human safety dataset for the blend. Reviews note that rigorous human safety data are scarce, with potential for serious harm, and the combination's safety is unproven [8]; a 2025 BPC-157 systematic review found no clinical safety data [7]. ### Does TB-500 cause cancer or promote tumor growth? Thymosin beta-4 is implicated in tumor angiogenesis and metastasis, so the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is an unresolved safety consideration drawn from the mechanism, not a demonstrated clinical effect of the blend. ### Is the BPC-157 / TB-500 blend safe for long-term use? Long-term human safety is unknown. BPC-157 has only three small human pilot studies [9], the TB-500 fragment has no completed controlled human trials [5], and the combination has never been studied long-term [7]. ### Is TB-500 bad for your heart? There is no validated human cardiac-safety data for TB-500 or the blend. Thymosin beta-4's vascular and migratory effects are studied preclinically [4], and 2025-2026 reviews stress that human safety data for these unapproved peptides are scarce [8]. The cardiac question is open, not answered. ## Regulatory and access ### Are BPC-157 and TB-500 FDA approved or banned by WADA? Neither is FDA-approved for human use, and the blend has no approved indication; FDA placed both components in 503A Category 2 of bulk substances flagged for significant safety risks, effective with the September 29, 2023 update [10]. Both are also WADA-prohibited — BPC-157 under S0 non-approved substances, TB-500 / thymosin beta-4 under prohibited peptide and growth-factor categories. ### Is Wolverine legal? Status depends on jurisdiction and context. Neither constituent is an FDA-approved medicine, both are currently 503A Category 2 bulk substances restricting pharmacy compounding access while that status stands [10] [11], and both are WADA-prohibited in sport. See the [Wolverine legal status and FDA 503A compounding access](/legal-status) page for the full record. ### Can you get BPC-157 from a compounding pharmacy? Under current FDA status, routine 503A pharmacy compounding of BPC-157 is restricted: FDA placed it in Category 2, outside the enforcement-discretion policy, effective with the September 29, 2023 list update [10]. BPC-157 is on the PCAC agenda for July 23-24, 2026 as a bulks-list candidate — a scheduled discussion, not a change in status [12]. ### What is the FDA 503A status of Wolverine? The blend is not an approved drug; both components are in FDA's 503A Category 2, placed there effective with the September 29, 2023 update, and both appear on the July 23-24, 2026 PCAC agenda as candidates under evaluation for the 503A bulks list [10] [12]. --- The Wolverine blend kept as a kiln-fired formulary entry — BPC-157 and TB-500 set down as two annotated specimens, their measured animal-model findings inked and their unproven join left in the warm margin, with the FDA 503A and WADA record pinned to the page and nothing here prescribed or sold.